Core Viewpoint - SurgePays, Inc. has announced a public offering of 2,000,000 shares of common stock at a price of $1.25 per share, aiming for gross proceeds of approximately $2.5 million before expenses [1] Company Overview - SurgePays, Inc. is a wireless and fintech technology company focused on providing essential mobile and financial services to subprime and underserved consumers [6] - The company operates a nationwide ecosystem that includes its own wireless brands and a proprietary point of sale platform, facilitating SIM activations, top-ups, financial transactions, and other digital services for prepaid and underbanked customers [6] Offering Details - The public offering consists of 2,000,000 shares priced at $1.25 each, with an option for underwriters to purchase an additional 300,000 shares [1] - The offering is expected to close on January 22, 2026, pending customary closing conditions [1] - R.F. Lafferty & Co., Inc. is the sole book-running manager for this offering [2] Future Growth Strategy - SurgePays is advancing into data-driven marketing and digital partnerships to monetize verified consumer engagement, aiming to create recurring, high-margin revenue streams [7] - The company aspires to become a leading digital marketplace and data intelligence platform for the one-third of America that relies on prepaid and subprime financial services [7]

Core Insights - Henry Schein, Inc. (HSIC) is a global provider of healthcare products and services with a market cap of $9 billion, serving dental and medical practitioners as well as alternate care sites worldwide [1][2] Financial Performance - HSIC shares have decreased 7.1% from its 52-week high of $82.49, but the stock has increased 13.7% over the past three months, outperforming the Health Care Select Sector SPDR Fund (XLV) which gained 12.1% in the same period [3] - Year-to-date, HSIC stock is up 10.7%, slightly lagging behind XLV's 11.8% increase, and has risen 4.7% over the past 52 weeks compared to XLV's 10.5% return [4] - On November 4, HSIC reported strong Q3 2025 results with adjusted EPS of $1.38, up from $1.22 a year earlier, and revenue of $3.34 billion, exceeding forecasts [5] Guidance and Analyst Outlook - The company raised its full-year 2025 adjusted EPS guidance to $4.88 - $4.96 and increased expected sales growth to 3% - 4% [5] - Despite underperformance relative to rivals like Quest Diagnostics (DGX), which returned 18.7% year-to-date, analysts maintain a moderately optimistic outlook for HSIC with a consensus rating of "Moderate Buy" and a mean price target of $77.64, representing a 1.3% premium to current levels [6]

Group 1 - The market maintains a positive outlook for the Magnificent Seven Shares, particularly Microsoft (MSFT), driven by increasing demand for AI and cloud computing, along with stable digital services revenues [1] - Invest Heroes LLC, a CIS-based research firm established in 2018, has gained recognition for its equity and fixed income research services, covering over 120 Russian, US, and Chinese stocks, and 200 Russian bonds [1] - The firm has achieved significant milestones, including participation in Refinitiv and Factset, and recognition as top analysts in the Refinitiv rating for several Russian companies [1] Group 2 - The research team at Invest Heroes LLC consists of 9 analysts, including 2 strategists, and has developed detailed business models for each company to provide forecasts that often outpace market expectations [1] - The firm serves a diverse client base, including institutional clients, asset managers, and approximately 3000 private clients [1] - Contact information for key personnel, including the CEO and Head of Research, is provided for further inquiries [1]